Navigation Links
CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
Date:8/28/2007

more information, please refer to http://www.topotarget.com .

Safe Harbor

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the expected benefits of belinostat, the use of belinostat in the treatment of AML and other diseases, and the conduct, enrollment, and data relating to CuraGen's Phase I/II clinical trial for belinostat may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Malvern initiates European user group meetings for chemical imaging
5. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Levi & ... Pharmaceutical, Inc. (NASDAQ: OHRP ) concerning possible violations ... issued by the Company in connection with its study ... TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. ... or by telephone at (212) 363-7500, toll-free: (877) ...
(Date:3/27/2015)... 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") (TSXV:MPH, ... approved the grant of an aggregate of 236,070 options ... consultants of the Company pursuant to the Company,s Stock ... expire on the tenth anniversary of the date of ... anniversary of the date of grant and 50,000 are ...
(Date:3/27/2015)... MONTREAL , March 27, 2015 /CNW Telbec/ - ... Research-Based Pharmaceutical Companies (Rx&D), welcomes the 2015-2016 ... of a working group on the biopharmaceutical industry. However, ... medicines budget. "We commend the government,s intent ... the announcement of measures to promote Quebec,s ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... , NEW YORK, Oct. 2 Business ... today released "The Role of ISO 9000 in Document ... certification for its Document Review Services, Quality Management System. ... developing a document review Quality Management System (QMS), where ...
... Oct. 1 Algos Therapeutics Inc., a Minnesota-based global ... of Dr. Ganesh Iyer as its new president and ... , "We were incredibly fortunate to have attracted such ... Algos," stated Gary Smaby, Algos Board Chair and managing ...
Cached Medicine Technology:BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes 'Quality Equals Defensibility' 2BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes 'Quality Equals Defensibility' 3Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO 2
(Date:3/27/2015)... 27, 2015 Ticket Down is a reputable ... Center in Omaha, Nebraska on Friday, May 8th and ... concert dates will be added in Omaha as Garth has ... , The Garth Brooks World Tour is continuing its run ... that Garth Brooks and Trisha Yearwood will bring their act ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... and analysis of the healthcare, regulatory and reimbursement landscape ... 2013 amounted to 316.1 million, having grown at a ... The country’s increasingly elderly population and corresponding increase in ... the growth of the pharmaceutical market, which was worth ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 California’s ongoing ... blizzards in Boston and the United States Northeast, are ... Earth warming global atmosphere is creating changes in the ... historical climatologist and former NASA researcher, speaking on the ... result is not only a warmer and dryer global ...
(Date:3/27/2015)... MN (PRWEB) March 27, 2015 ... Minnesotans for Healthy Kids Coalition Lobby Day to ... Statewide Health Improvement Program (SHIP). Everlast Climbing ... 2015 PE Bill SF343/HF498 which would strengthen physical ... annual student assessments and other measures to strengthen ...
(Date:3/27/2015)... 2015 Smile Brands Inc. ( http://www.smilebrands.com ... support services to dental groups in the United States, ... Castle Dental office in Hendersonville, TN. , ... this new Castle Dental office provides families with a ... in comprehensive, quality dental care. Hendersonville marks the eleventh ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3
... Common Office Environments StudiedBOULDER, Colo., May 11 ... company that provides comprehensive and cost-effective ergonomic interventions ... improve productivity, today announced that John Wiley and ... journals has published a book titled "Safety Manager,s ...
... an invited panelist in the second annual SOA in Healthcare conference to ... ... Plano, Texas (PRWEB) May 11, 2009-- Corepoint Health,s CTO, Dave Shaver, will ... to be held on June 2 - 4 in Chicago, Illinois. ...
... - Easy-to-swallow formulation provides important new alternative for patientsRESEARCH ... GSK ) announced today that the U.S. Food ... Orally Disintegrating Tablets. Lamictal ODT uses a ... a tablet that has a pleasant taste and disintegrates ...
... 11 Lambert, Edwards & Associates (LE&A) ... growing roster of health care clients.Aspirus is a community-directed ... care services to residents in north-central Wisconsin and the ... is consistently recognized as one of the nation,s premier ...
... Services and ProCitius Research jointly announce a strategic alliance created to ... ... Toronto, Canada and Chennai, India (PRWEB) - Dalton Pharma ... provide clients with contract chemistry services of exceptional value. ...
... HHS Report Released During National Women,s Health Week Points ... new report released today on gender-based differences in mental ... men to suffer from major depression. The report ... the effect trauma and violence can have on long ...
Cached Medicine News:Health News:Office Ergonomics Book Reveals Early-Stage Solutions 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 3Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 2Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 3Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 4Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 5Health News:FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets 6Health News:Lambert, Edwards & Associates Named Agency of Record for Aspirus, Inc. 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 2Health News:Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 3Health News:Women at Greater Risk for Depression and Anxiety 2Health News:Women at Greater Risk for Depression and Anxiety 3
Ideal for breast compression and contouring breast cups....
Ideal for breast compression with adjustable hook and eye closure....
Female Mini-VEST, Front Closure, X-Firm...
Male Support Brief...
Medicine Products: